[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://www.allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 649097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 994595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 260500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 45, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 747390, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Yinlin  Chen", "title": "Senior Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.69, "open": 1.67, "dayLow": 1.53, "dayHigh": 1.7, "regularMarketPreviousClose": 1.69, "regularMarketOpen": 1.67, "regularMarketDayLow": 1.53, "regularMarketDayHigh": 1.7, "payoutRatio": 0.0, "beta": 1.023, "forwardPE": -1.2050359, "volume": 4357555, "regularMarketVolume": 4357555, "averageVolume": 5495765, "averageVolume10days": 3213210, "averageDailyVolume10Day": 3213210, "bid": 1.67, "ask": 1.68, "bidSize": 1, "askSize": 1, "marketCap": 363918848, "fiftyTwoWeekLow": 1.32, "fiftyTwoWeekHigh": 4.63, "priceToSalesTrailing12Months": 16541.766, "fiftyDayAverage": 1.9312, "twoHundredDayAverage": 2.39135, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 165457408, "profitMargins": 0.0, "floatShares": 156219865, "sharesOutstanding": 217264992, "sharesShort": 39095990, "sharesShortPriorMonth": 32048327, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.1865, "heldPercentInsiders": 0.17728001, "heldPercentInstitutions": 0.77838, "shortRatio": 4.24, "shortPercentOfFloat": 0.2622, "impliedSharesOutstanding": 209672000, "bookValue": 1.989, "priceToBook": 0.84213173, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -257590000, "trailingEps": -1.32, "forwardEps": -1.39, "enterpriseToRevenue": 7520.791, "enterpriseToEbitda": -0.679, "52WeekChange": -0.6185101, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 1.675, "targetHighPrice": 14.0, "targetLowPrice": 3.0, "targetMeanPrice": 8.75, "targetMedianPrice": 8.5, "recommendationMean": 1.6875, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 292476000, "totalCashPerShare": 1.346, "ebitda": -243843008, "totalDebt": 90756000, "quickRatio": 8.287, "currentRatio": 8.541, "totalRevenue": 22000, "debtToEquity": 21.497, "revenuePerShare": 0.0, "returnOnAssets": -0.27011, "returnOnEquity": -0.55134, "grossProfits": -192276992, "freeCashflow": -99133376, "operatingCashflow": -200300000, "revenueGrowth": -1.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -11703.728, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -0.88758016, "regularMarketPrice": 1.675, "marketState": "REGULAR", "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "corporateActions": [], "regularMarketTime": 1742412199, "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": -0.015000105, "regularMarketDayRange": "1.53 - 1.7", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 5495765, "fiftyTwoWeekLowChange": 0.3549999, "fiftyTwoWeekLowChangePercent": 0.26893932, "fiftyTwoWeekRange": "1.32 - 4.63", "fiftyTwoWeekHighChange": -2.9550002, "fiftyTwoWeekHighChangePercent": -0.63822895, "fiftyTwoWeekChangePercent": -61.851013, "earningsTimestamp": 1741896120, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "earningsCallTimestampStart": 1741899600, "earningsCallTimestampEnd": 1741899600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.39, "epsCurrentYear": -1.08658, "priceEpsCurrentYear": -1.541534, "fiftyDayAverageChange": -0.25620008, "fiftyDayAverageChangePercent": -0.13266367, "twoHundredDayAverageChange": -0.7163501, "twoHundredDayAverageChangePercent": -0.29955885, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]